Abstract
We investigated whether the addition of metformin to the treatment of overweight and obese individuals further reduces the incidence of type2 diabetes mellitus (T2 DM), prediabetes and metabolic syndrome (MetS) and improves cardiovascular disease (CVD) risk factors (RFs).
Design and methods: We studied 366 adults (mean age 53.0±0.5 SE years, and mean BMI 32.3±0.2 SE Kg/m2
) without CVD. All subjects received lifestyle recommendations and drug management of CVD-RFs, whilst 95 of them were additionally given metformin. The follow-up period lasted 12 months.
Results: At the end of the study the frequency of T2 DM in the metformin and non-metformin group was 1.1 and 8.1%, respectively (risk difference=−7% with 95% CI from −12.7% to −1.4%, p=0.012). Participants with prediabetes displayed a greater reduction in the incidence of T2 DM after taking metformin compared to those who had not received this drug (risk difference=−18.5% with 95%CI from −33.1% to −3.9%, p=0.010). Metformin had a similar beneficial impact on subjects with MetS (risk difference=−12.9% with 95% from −25% to −0.7%, p=0.040) and this was attributed to the greater increase in HDL-C (p=0.046) and decrease in fasting plasma glucose levels (p=0.024). Metformin also achieved a greater reduction in total cholesterol and LDL-C levels (metformin vs. non-metformin treated subjects: −31.9 vs. −17.3 mg/dl, p=0.001, and −26.2 vs. −15.9 mg/dl, p=0.006, respectively).
Conclusions: Metformin reduces the occurrence of T2 DM in overweight and obese non-diabetic adults and decreases the rate of MetS by improving the CVD risk factor profile.
Key words
metformin - type 2 diabetes mellitus - prediabetes - metabolic syndrome
References
1
Kuczmarski RI, Flegal KM, Campbell SM. et al .
Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991.
JAMA.
1994;
272
205
2
Sainaghi PP, Castello L, Bergamasco L. et al .
Metabolic characteristics of glucose intolerance: the critical role of obesity.
Exp Clin Endocrinol Diabetes.
2008;
116
86-93
3
Alberti KG, Zimmet P, Shaw J.
The metabolic syndrome: a new worldwide definition.
Lancet.
2005;
366
1059-1062
4
Schwarz PE, Lindstrom J, Kissimova-Scarbeck K. et al .
DE-PLAN project.
Exp Clin Endocrinol Diabetes.
2008;
116
167-172
5
Pfeiffer AF.
Adipose tissue and diabetes therapy: do we hit the target?.
Horm Metab Res.
2007;
39
734-738
6
The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators.
.
Effect of rosiglitazone of the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized control trial.
Lancet.
2006;
368
1096-1105
7
Chiasson JL, Josse RJ, Gomis R. et al .
Acarbose for prevention of type2 diabetes mellitus: the STOP-NIDDM randomized trial.
Lancet.
2002;
359
2072-2077
8
Knowler WC, Barrett-Connor E, Fowler SE. et al .
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
N Engl J Med.
2002;
346
393-403
9
Diamantopoulos EJ, Andreadis EA, Tsourous GI. et al .
Metabolic syndrome and prediabetes identify overlapping but not identical populations.
Exp Clin Endocrinol Diabetes.
2006;
114
377-383
10
Diamantopoulos EJ, Andreadis EA, Tsourous GI. et al .
Intermediate postchallenge hyperglycemia in overweight and obese subjects: a new marker of impaired glucose regulation?.
Angiology.
2006;
57
709-716
11
Calle EE, Thun MJ, Petrelli JM. et al .
Body mass index and mortality in a prospective cohort of US adults.
N Engl J Med.
1999;
341
1097-1105
12
Friedwald WT, Levy RI, Fredrickson DS.
Estimation of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge.
Clin Chem.
1972;
18
499-502
13 Hainline
Jr
A, Karon J, Lippel K.
eds. Manual of Laboratory Operations, ed. 2, Lipid Research Clinics Program, Lipid and Lipoprotein Analysis . Washington, DC: US Department of Health and Human Services, Public Health Service, National Institutes of Health (updated 1983)
14
Multicenter study of Tina-quant Albumin in urine and β-N-acetyl-glycosaminidase (β-NAG) in urine. Workshop Munich, November 29–30, 1990.
Wien Klin Wschr.
1991;
103
((Suppl. 189))
1-64
15
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
.
Follow-up report on the diagnosis of diabetes mellitus.
Diabetes Care.
2005;
28
S37-S42
16
The Food Guide Pyramid Washington, DC.
.
, Department of Agriculture, Center for Nutrition Policy and Promotion, 1996. (Home and Garden Bulletin no. 252.)
17
Step by step: eating to lower your high blood cholesterol
. Bethesda, Md.: National Heart, Lung, and Blood Institute Information Center 1987
18
Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Final report
.
Circulation.
2002;
106
3143-3421
19
Chobanian AV, Bakris GL, Black H. et al .
Seventh Report Of The Joint National Committee On Prevention, Detection, Evaluation, And Treatment Of High Blood Pressure.
Hypertension.
2003;
42
1206-1252
20
Palumbo PJ.
Metformin: Effects on cardiovascular risk factors in patients with Non-Insulin-Dependent Diabetes Mellitus.
J Diab Complicat.
1998;
12
110-119
21
Maglalhaes FO, Gouveia LM, Torquato MT. et al .
Metformin increases blood flow and forearm glucose uptake in a group of non-obese type 2 diabetes patients.
Horm Metab Res.
2006;
38
513-517
22
Kirpichnikov D, MacFarlane SI, Sowers JR.
Metformin: An Update.
Ann Intern Med.
2002;
137
25-33
23
Giugiliano D, Acampora R, DeRosa N. et al .
Metformin improves glucose lipid metabolism and reduces blood pressure in hypertensive obese women.
Diabetes Care.
1993;
16
1387-1390
24
Stumvoll M, Nurjahan N, Perriello G. et al .
Metabolic effects of metformin in non-insulin dependent diabetes mellitus.
N Engl J Med.
1995;
333
550-554
25
Rains SGH, Wilson GA, Richmond W. et al .
The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes.
Diabetic Med.
1988;
5
653-658
26
DeFronzo RA, Goodman AM.
and the Multicenter Metformin Study Group
.
Efficacy of metformin in patients with non-insulin dependent diabetes mellitus.
N Engl J Med.
1995;
333
541-549
27
Wu MS, Johnston P, Sheu WH-H. et al .
Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients.
Diabetes Care.
1990;
13
1-8
28
Landin K, Tengborn I, Smith U.
Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors.
J Intern Med.
1991;
229
181-187
29
Nathan D, Davidson BM, DeFronzo RA. et al .
Impaired fasting glucose and impaired glucose tolerance. Implications for care.
Diabetes Care.
2007;
3
753-759
30
Xiang GD, Sun HL, Hou J. et al .
Acute hyperglycemia rapidly suppresses endothelium-dependent arterial dilation in first-degree relatives of type 2 diabetic patients.
Exp Clin Endocrinol Diabetes.
2008;
116
112-117
31
Grant RW, Meigs JB.
Prevalence and treatment of low HDL choles-terol among primary care patients with type 2 diabetes. An unmet challenge for cardiovascular risk reduction.
Diabetes Care.
2007;
30
479-484
Correspondence
Assoc. Prof. E. J. DiamantopoulosMD
10 Oitis Street
154 52 Paleo Psychiko
Athens
Greece
Telefon: +30/210/725 88 62 or 21 007 220 15 29
Fax: +30/210/725 88 62
eMail: Dpathologiki@evaggelismos-hosp.gr